• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LBT 0.00% 8.6¢

LBT INNOVATIONS LIMITED - Corporate Spotlight

LBT Innovations is a ground-breaking designer of advanced technology solutions for the... LBT Innovations is a ground-breaking designer of advanced technology solutions for the medical industry. We specialise in combining artificial intelligence, image analysis and software engineering to improve healthcare delivery. Our product, APAS® Independence, is a global first solution for automated reading of microbiology culture plates.More

Corporate Spotlight

LBT Innovations is a ground-breaking designer of advanced technology solutions for the medical industry. We specialise in combining artificial intelligence, image analysis and software engineering to improve healthcare delivery.
View the full Corporate Spotlight arrow Created with Sketch.

LBT SALES IMPROVES AS US REOPENS

LBT SALES IMPROVES AS US REOPENS

arrow-down-2 Created with Sketch.

LBT Innovations (ASX:LBT) sales momentum improves as US reopens

Health Care

ASX:LBT

 

  • LBT Innovations (LBT) says its sales momentum is improving as the US begins to reopen in full after the COVID-19 pandemic
  • The medtech business' access to US labs is improving, with sales executives now able to meet face-to-face as travel restrictions ease
  • Meanwhile, the healthcare stock continues to advance the commercialisation of its APAS Independence technology
  • LBT is aiming to appoint a US distributor for the microbiology tech between July and September this year

LBT Innovations (LBT) said sales momentum is improving as the US begins to reopen from the COVID-19 pandemic.


The medical technology business released a US commercial progress update on Monday, noting access to US labs is improving.


The company said its sales executives are finally able to meet face-to-face with clients after travel restrictions previously delayed these interactions.


The healthcare stock said the update was "encouraging" as it continues to advance the commercialisation of its APAS Independence technology.


LBT is aiming to appoint a US distributor for the microbiology tech between July and September this year.


It's already signed a Master Product Agreement with AdventHealth Medical Group and also won a spot to showcase its APAS tech at the Vizient Innovative Technology Exchange.


"The ability to travel again in the US in recent weeks is really encouraging as there is no better way to showcase our technology and engage with potential customers than for our sales team to meet them in person in their labs," CEO Brent Barnes said.


"We are pleased with our first agreement with AdventHealth and also the opportunity that will be provided to us at the highly regarded Vizient Technology Exchange.


"We remain confident of appointing a highly credentialled distributor for the APAS Independence in the United States in Q3 2021 and accelerating our sales traction once appointed.”


Read the Full Article on The Market Herald here

LBT CLOSES IN ON U.S DISTRIBUTOR

arrow-down-2 Created with Sketch.

LBT Innovations (ASX:LBT) closes in on appointing U.S. distributor

Health Care

ASX:LBT
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald
CEO & Managing Director, Brent Barnes
Source: LBT Innovations

  • LBT Innovations (LBT) has posted its Q3 FY21 report, announcing it's closing in on appointing a U.S. distributor for APAS Independence technology
  • The healthcare stock's joint venture business, Clever Culture Systems (CCS), is progressing the appointments with a distributor expected to be signed by the end of the October quarter
  • In terms of sales, LBT said COVID-19 continues to impact its ability to facilitate sales due to travel restrictions and some hospitals remaining closed to guests
  • LBT ended March 31 well-funded with $11.3 million in the bank, enough cash to keep the company going for another 94.7 quarters
  • The business has also begun the process of rejuvenating its board, with recruitment underway to find a new chair and non-executive director


LBT Innovations (LBT) has posted its Q3 FY21 report, announcing it's closing in on appointing a U.S. distributor for its APAS Independence technology.


The healthcare stock's joint venture business, Clever Culture Systems (CCS), is progressing the appointment.


CCS said due diligence and contract discussions are now underway and its aiming to have a distributor signed by the end of October quarter.


In terms of sales, LBT said COVID-19 continues to impact its ability to facilitate sales due to travel restrictions and some hospitals remaining closed to guests.


As a results, CCS has undertaken a review of its sales and marketing strategy with the objective to improve commercialisation timelines and outcomes.


"We have been upfront about the challenge of getting into labs, arranging placements and evaluations of the APAS Independence and then actually completing sales has been unfavourably impacted by COVID-19," CEO Brent Barnes said.


"We are handling this in multiple ways including a finer focus on potential early technology adopters; building supporting clinical evidence from labs such as The Doctor’s Laboratory, SA Pathology and Labor Dr Wisplinghoff and using this time to complete negotiations and due diligence with potential US distributors," he added.


Meanwhile, LBT ended March 31 well-funded with just under $11.3 million in the bank, enough cash to keep the company going for another 94.7 quarters.


The business has also begun the process of rejuvenating its board, with recruitment underway to find a new chair and non-executive director for LBT.


Read the Full Article on The Market Herald here

LBT SECURES UK SALE WITH SHL SUBSIDIARY

arrow-down-2 Created with Sketch.

LBT Innovations (ASX:LBT) secures first U.K. sales with Sonic Healthcare (ASX:SHL) subsidiary

Health Care

ASX:LBT 

  • LBT Innovations (LBT) has sold two of its APAS Independence instruments for use in a Sonic Healthcare (SHL) subsidiary laboratory in the U.K.
  • The instruments were sold through LBT's s joint venture company, Clever Culture Systems, to Health Services Laboratory for use at its Halo Facility in London
  • The deal marks the first U.K sales for the Australian medical technology company, with the instruments set to perform screening of high volume urine and MRSA specimens and at the facility
  • In addition, the data generated from the clinical evaluation of MRSA completed by HSL has been accepted as a poster presentation for the European Congress of Clinical Microbiology and Infectious Diseases conference in July
  • LBT Innovations shares are up 12.7 per cent following the announcement, trading at 8 cents per share

LBT Innovations (LBT) has sold two of its APAS Independence instruments for use in a Sonic Healthcare (SHL) subsidiary laboratory in the U.K.


The instruments were sold through LBT's s 50 per cent owned joint venture company, Clever Culture Systems, to Health Services Laboratory to be used in its Halo Facility in London.


The deal marks the first U.K sales for the Australian medical technology company.


According to LBT, the laboratory is part of a public-private partnership and is a flagship U.K. laboratory and centre of excellence for The Doctors Laboratory, a subsidiary of Sonic Healthcare.


The device APAS Independence devices are set to perform screening of high volume urine and MRSA specimens and at the facility and will sit alongside the already installed BD Kiestra Total Lab Automation (TLA) solution.


In addition, the data generated from the clinical evaluation of MRSA completed by HSL has been accepted as a poster presentation for the European Congress of Clinical Microbiology and Infectious Diseases conference to be held virtually in July 2021.


LBT explains the APAS device uses artificial intelligence to screen culture plates and divides them into three categories: negatives, positives, and those to be reviewed.


Health Services Laboratory's Head of Department Alan Spratt said the technology exceeded their expectations during testing.


While LBT Innovation's Managing Director Brent Barnes said the team was thrilled with the arrangement.


"This is a demonstration of the positive experience we have consistently seen from laboratories who have trialled our technology," he commented.


"As a technology leader in microbiology in the UK, this sale is also another key step to us building awareness and early adoption of the APAS technology in the UK marketplace," he added.


To read the full article on The Market Herald click here.

LBT SHAKES UP BOARD OF DIRECTORS

arrow-down-2 Created with Sketch.


LBT Innovations (ASX:LBT) shakes up Board of Directors

Health Care

ASX:LBT    
LBT Innovations - (ASX:LBT) - Outgoing Chairman, Kate Costello - The Market Herald

  • Medical technology business LBT Innovations (LBT) has revealed its plans for the renewal of the company’s Board of Directors
  • The company received clear and consistent AGM feedback about the tenure of certain Board Directors, including the Chair
  • During LBT’s Board renewal process, Chairman Kate Costello and Non-Executive Director Caroline Popper will both retire from the Board
  • Both Kate and Caroline are working to find a suitable applicant to replace the current Chair of the Board

Medical technology business LBT Innovations (LBT) has revealed its plans for the renewal of the company’s Board of Directors.


On November 25, 2020, the company held its Annual General Meeting (AGM), during which its shareholders voted on a number of resolutions. During this AGM, LBT received what it described as clear and consistent feedback about the tenure of Board Directors, including the Chair. 


While LBT began discussions about the succession of the Chair last year, the company has updated its plans and begun the active process of Board renewal. 


This process will ensure that those who are appointed to Board have the suitable qualifications needed to lead LBT and drive the company’s commercialisation of its APAS technology. 


As a result of this renewal process, the company’s Chairman Kate Costello and Non-Executive Director Caroline Popper will both retire from their positions on the Board this year. 


Caroline, who joined LBT’s Board in March 2012, will step down from her role in May 2021. For now, she is leading the search for a suitable applicant to replace the current Chair of the Board.


After the new Chair-Elect is appointed, a short but orderly transition period will take place. During this transition, outgoing Chair Kate Costello will work with the Board on the audit of the 2020/2021 financial year and Annual Report.


After the transition period has ended, Kate will step down from her role. 


Kate commented on the company’s process to revitalise its Board of Directors.


“We have listened to the feedback from shareholders who have expressed concern about the tenure of some directors, myself included,” she said.


“The Board had previously commenced succession discussions and I am committed to working with the current Board to identify the best possible candidates for the company and work with my successor to transition the Chair of the Board in an orderly fashion,” she added.



Read the full article on The Market Herald here.

LBT soar on APAS Independence sale

arrow-down-2 Created with Sketch.

LBT Innovations’ (ASX:LBT) shares soar on APAS Independence sale

Health Care

ASX:LBT    MCAP $34.59M 
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald
CEO & Managing Director, Brent Barnes
Source: LBT Innovations


  • Biotech company LBT Innovations (LBT) was up more than 14 per cent today after selling its APAS Independence platform to the Limbach Group in Germany
  • Significantly, this marks the first sale of APAS Independence to Limbach's technology leader, Labor Dr Gärtner
  • The sale follows a six-month evaluation of the technology and was completed by LBT's joint venture company, Clever Culture Systems
  • It includes a five-year software licence for the MRSA analysis module, as well as an ongoing service contract
  • APAS Independence is LBT's platform technology which automates and speeds-up culture plate screening 
  • LBT is still up a healthy 14.6 per cent and shares are trading for 13.8 cents each

Biotech company LBT Innovations (LBT) was up more than 14 per cent today after selling its APAS Independence platform to the Limbach Group in Germany.


The Limbach Group is made up of over 30 laboratories and is the largest network of laboratories in Germany. 

Significantly, this marks the first sales of APAS Independence to Limbach's technology leader, Labor Dr Gärtner. 


Labor Dr Gärtner is one of the largest and most efficient laboratories in southern Germany, offering full diagnostic services to meet demands of the local community. 


The sale follows a six-month evaluation of the technology and was completed by LBT's joint venture company, Clever Culture Systems (CCS). 


It includes a five year software licence for the MRSA analysis module as well as an ongoing service contract. 

Installation, calibration and maintenance will be completed by CCS's service provider to ensure the technology is operational. 


"This sale commences an exciting relationship, not just just with Labor Dr Gärtner, but with the broader Limbach Group," CEO and Managing Director Brent Banes said. 


"We look forward to supporting the laboratory through the installation process and continuing to work with them to ensure ongoing success which we expect will be keenly watched by the broader Limbach Group," he added. 


APAS (Automated Plate Assessment System) Independence is a platform technology which automates culture-plate screening and interpretation. 


Thousands of agar plates are assessed every day and each one has to be thoroughly examined by a microbiologist. 

APAS Independence speeds-up this process by automatically screening, interpreting, and sorting the plates — freeing up the microbiologist's time. 


Read the full article on The Market Herald here: https://themarketherald.com.au/lbt-innovations-asxlbt-shares-soar-on-apas-independence-sale-2020-10-12/

Installation in a post-COVID world

arrow-down-2 Created with Sketch.

LBT Innovations (ASX:LBT): Disruptive diagnostics installation in a post-COVID world

Sponsored

LBT Innovations (ASX:LBT): Disruptive diagnostics installation in a post-COVID world
Source: LBT Innovations


  • The Health Services Laboratories (HSL) Halo lab is one of the most prestigious medical research facilities across the globe
  • The building staffs 1000 people over 100,000 square feet of laboratories in the wider MedCity health sciences hub in London
  • ASX-listed LBT Innovations recently installed its Automatic Plate Assessment System (APAS) device in the Halo building
  • What's more, the company had the tech installed completely remotely
  • Not only is this a major endorsement of LBT's APAS device, but it's evidence of the company's disruptive and adaptive strategy for a post-COVID-19 era

Across the world, there are a handful of medical research labs that outclass all others in their field.

One of these such facilities is the Health Services Laboratories (HSL) Halo building in the United Kingdom.


HSL is a partnership between Royal Free London NHS Foundation Trust, the University College London Hospitals NHS Foundation Trust, and The Doctors Laboratory — a subsidiary of ASX-listed radiology and pathology giant Sonic Healthcare (SHL).


The HSL partnership is renowned for the quality of its resources, with only the best equipment, the smoothest systems, and the brightest minds being used across its lab suite.


In fact, Dr Vanya Gant, UCLH's Divisional Clinical Director for Infection, said he has never seen a facility like HSL's in over three decades.


"In over 30 years of working as a physician in the National Health Service I have never, ever, ever seen such investment and energy and optimism and focus on moving to the next generation of what can be done with diagnostic medicine."

Dr Vanya Gant, UCLH Divisional Clinical Director for Infection, September 2016


However, Sonic is not the only ASX-listed medical stock exposed to this cutting-edge facility.


LBT Innovations (LBT) installed its Automatic Plate Assessment System (APAS) device in HSL's world-class Halo laboratory in July 2020.


The Halo lab is the flagship lab of the HSL building; the U.K.'s heart of pathology and diagnostic research. The facility is home to more than 100,000 square feet of laboratories and staffs 1000 people.


The building is part of the wider MedCity health sciences hub in London, which was created in 2014 as a way to connect the U.K.'s leading medical research organisations.


Why LBT?

So, if the Halo facility is so prestigious, why install the tech of a small-cap Australian company?

It all comes down to the potential of the APAS device to streamline key areas of microbiology.


Essentially, LBT's APAS tech uses artificial intelligence to automatically read and categorise culture plates. Ordinarily, microbiologists need to scour through hundreds of plates to find significant bacterial colonies which they can then study to discover what causes different diseases and illnesses in the body.


The APAS device does this automatically, with impressive accuracy, and at least three times quicker than the average microbiologist.

In July, HSL's Head of Department, Infection Sciences, Alan Spratt said the organisation was excited to be conducting the first U.K. trial of the APAS machine.


"The application of assisted intelligence in a high-volume lab like ours has the potential to streamline laboratory workflows bringing benefits to staff, quality, turnaround times and consequentially patient outcomes," Alan said.

This is a massive vote of confidence for the APAS device.


For LBT, this is all part of the company's strategy of getting its tech into the hands of the best researchers and laboratories. Importantly, LBT was able to execute this strategy despite the challenges presented by the COVID-19 pandemic.


Disruptive adaptation

With international borders sealed shut across the globe, July 2020 was an unusual time for a company to install its tech in an overseas lab.


However, LBT was able to get the job done 100 per cent remotely with the help of its recently-appointed service provider, oneservice.

The LBT team worked closely — via Zoom — with the HSL and oneservice teams to install the APAS tech in just two days.


This proves two things for LBT: firstly, the company's tech is so intuitive and easy to install that it does not need weeks of planning and careful navigation but rather just days and remote management oversight to get it up and running. Secondly, the company is flexible enough to achieve its goals in the midst of challenges instead of waiting for the waters to calm down.


While all eyes are on digital and non-contact healthcare in light of COVID-19, LBT has started to disrupt a different sector of the health and wellness world: tech installation.


With the world's first non-contact diagnostics installation going off without a hitch, the possibilities unlocked by LBT are endless.

The coronavirus might be keeping people indoors, but LBT has proven that the transition to online and at-home work has left myriad sectors primed for disruption.


While the APAS device is enough to write home about on its own, the company's strategy execution is laying down the foundations for LBT to make the most of the post-COVID world.


https://themarketherald.com.au/lbt-innovations-asxlbt-disruptive-diagnostics-installation-in-a-post-covid-world-2020-09-02/

GETTING THE BEST TECH INTO BEST PLACES

arrow-down-2 Created with Sketch.

LBT Innovations (ASX:LBT): Getting the best tech into the best places

Sponsored

ASX:LBT 
LBT Innovations (ASX:LBT): Getting the best tech into the best places
Source: LBT Innovations


When it comes to innovation in medical technology, it's often the case that the optimisation of existing practises is just as important as a flashy new invention.


In the world of pathology, for example, microbiologists often need to scour through hundreds of culture plates to find significant bacterial colonies which they can then study to discover what causes different diseases and illnesses in the body.


The problem is that up to 95 per cent of these culture plates are negative — meaning that highly skilled microbiologists look at plates that don’t require this skill. Of course, if just five out of 100 plates can provide doctors with information that can save a person's life, it's worth quickly going through the 95 dud plates just to study the important ones.


But what if the screening process could be automated and optimised so microbiologists can devote all their time to the important plates?


This was the thought process behind ASX-listed LBT Innovations' Automated Plate Assessment System (APAS).


APAS optimisation

The device uses artificial intelligence (AI) to automatically screen culture plates and divides them into three categories: negatives, positives, and those to be reviewed.


The APAS system does this in a fraction of the time it would ordinarily take a microbiologist and with impressive accuracy. The device can read and interpret up to 200 plates per hour, which is at least three times quicker than the average microbiologist.


LBT partnered with the Australian Institute of Machine Learning to develop the APAS device, which became the world's first artificial intelligence diagnostic medical device to receive U.S. Food and Drug Administration (FDA) Class II clearance in 2016. This process involved a 10,000-patient clinical trial performed in Australia and the U.S.


LBT's major market opportunity

The first-of-its-kind device has applications across the pathology market. And that's no small market, either.

The pathology umbrella covers a range of lucrative markets that LBT's APAS device is primed to disrupt.


Take the global in-vitro diagnostics market which, according to research from Grandview, was worth US$60.8 billion (roughly A$85 billion) in 2019. A February 2020 report from Grandview expects this industry to grow at a compound annual growth rate (CAGR) of 4.4 per cent from 2020 to 2027.


Similarly, Grandview's research says the AI in healthcare market was worth US$2.5 billion (roughly A$3.5 billion) in 2018 but has a predicted CAGR of a whopping 41.5 per cent through to 2025.


The market for clinical microbiology is expected to be worth US$16.7 billion (roughly A$23 billion) by 2025.

And, of course, it's not just about the size of the market. Medicine is a conservative industry; the less efficient your tech and the more mistakes you make, the more likely someone is to die.


Thus, by removing the need for microbiologists to trawl through negative plates, they can attend to significant specimens faster and ultimately reduce the turnaround time for critical results. This has an obvious impact on patient care and clinical outcomes.

And it's not just LBT touting the abilities of this tech; the APAS device has been picked up in some of the world's top research labs.


Read the full article on The Market Herald here: https://themarketherald.com.au/lbt-innovations-asxlbt-getting-the-best-tech-into-the-best-places-2020-08-27/

LBT SIGNS MARKETING AGREEMENT

arrow-down-2 Created with Sketch.

7th July 2020 - The Market Herald


  • Meditech company LBT Innovations (LBT) has signed a marketing agent agreement with Beckman Coulter for the marketing of the APAS Independence in Europe
  • APAS Independence is a platform technology that automates culture plate screening 
  • Beckman Coulter develops, manufacturers, and markets products that simplify and automate complex biomedical testing
  • Under the three-year agreement, Coulter will act as the marketing agent for APAS Independence and will receive a fixed referral fee for each sale 
  • This agreement will initially focus on the United Kingdom, France, and Germany, but the ability exists to expand into additional countries
  • After entering a trading halt, LBT is steady on the market and shares are trading for 19 cents each 

Meditech company LBT Innovations (LBT) has signed a marketing agent agreement with Beckman Coulter for the marketing of the APAS Independence in Europe. 


Beckman Coulter develops, manufacturers, and markets products that simplify and automate complex biomedical testing. 

Under the three-year agreement, Beckman Coulter will act as the marketing agent for APAS Independence and will receive a fixed referral fee from CCS for each sale and it may receive incentives for the completion of early sales. 


CCS (Clever Culture Systems) is LBT Innovations' 50:50 joint venture company in the commercialisation of APAS and it will take charge of the sales, installation, and maintenance of the product. 


This agreement will initially focus on the United Kingdom, France, and Germany, but the ability exists to expand to additional countries. 

"The management team has been working tirelessly with our counterparts at Beckman Coulter to deliver this collaboration, and we are excited to formalise this agreement," CEO and Managing Director Brent Barnes said. 


"This represents a significant step forward in our commercialisation strategy for the technology, adding the scale and strength of the Beckman Coulter brand to support our sales efforts in the region," he added. 


What is APAS Independence? 

APAS (Automated Plate Assessment System) Independence is a platform technology that automates culture-plate screening and interpretation. 


Thousands of agar plates are assessed every day and each one has to be thoroughly examined by a microbiologist. 

APAS Independence speeds-up this process by automatically screening, interpreting, and sorting the plates. This frees up the microbiologist's time. 


A soft launch is expected in late 2020, which will then be followed by European meetings in 2021, with organisations like the European Congress of Clinical Microbiology and Infectious Diseases. 


After entering a trading halt, LBT is steady on the market and shares are trading for 19 cents each. 


7th July 2020 - The Market Herald

FIRST SALE IN UNITED STATES

arrow-down-2 Created with Sketch.

FIRST SALE OF APAS® INDEPENDENCE IN UNITED STATES

ASX Release 9th June 2020


Hennepin County Medical Center purchases APAS® Independence

Adelaide, Australia, 09 June 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the first sale of an APAS® Independence in the United States to Hennepin County Medical Center (HCMC).


First U.S. Sale

The sale of the APAS® Independence has been completed following the installation of the middleware driver for APAS® connecting the instrument to the HCMC Laboratory Information Management System, which enables the automated reporting capability of the APAS® technology. The APAS® driver developed by Data Innovations has been successfully interfaced by HCMC and is now in a testing and validation phase prior to expected routine clinical use of the urine analysis module.

The sale was made directly to HCMC by LBT’s 50% owned joint venture company, Clever Culture Systems (CCS). HCMC has entered into an annual software license for the FDA cleared urine analysis module and a 5-year service agreement, both on normal commercial terms. The commercial terms for the sale of the APAS® instrument reflect that it is a pre-production model installed approximately 2 years ago.


Data Innovations Middleware Connection

The connection of the APAS® Independence to a customer’s Lab Information System (LIS) is required for routine clinical use and critical for labs to realise the full benefits of the instrument. This connection of the APAS® Independence to the LIS using the Data Innovations middleware is another global first. Establishing this middleware platform will support future APAS® installations with Data Innovations existing customer base. Data Innovations have installations in approximately 65% of all laboratories in the United States.


APAS® Independence at Hennepin Health Medical Center

HCMC in Minneapolis operates a nationally recognised Level I Adult Trauma Centre and Level I Paediatric Trauma Centre with primary care clinics located in Minneapolis and across Hennepin County. The HCMC Microbiology Laboratory provides a full range of diagnostic testing and reporting services and has purchased the APAS® Independence with associated urine analysis module to support their daily culture plate workflow. HCMC is a medium sized clinical laboratory processing approximately 500 specimens a day including 300 urine plates for analysis.


Director of Microbiology, Dr Glen Hansen, has a reputation for innovation and leading the industry with the implementation of cutting-edge technologies. Over the past 2 years, HCMC has been acting as a centre of excellence for APAS®, supporting the development of new analysis modules and presenting data at scientific conferences such as the American Society of Microbiology Microbe and the European Congress of Clinical Microbiology and Infectious Diseases.


HCMC Director of Microbiology, Dr Glen Hansen said:

“The ability for us to automate the reading of our culture plates with the APAS® Independence has increased the work efficiency through the laboratory and has motivated staff who now have more time for other activities. It has been a real pleasure to work with the teams from LBT and CCS over the past two years. Their commitment and excitement towards the technology is obvious and I look forward to continuing the collaboration into the future.”


LBT CEO and MD, Brent Barnes said:

“We are thrilled for HCMC to be the site of our first APAS® sale in the United States given their status and reputation which will no doubt help provide further commercial validation. Dr Hansen has been a great advocate for the technology and the purchase reflects the positive impact the technology has had within their lab. We continue to work hard with other laboratories in the region as we look to target further U.S. commercial sales.”


LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation.


 Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company’s second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT’s 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. 


The APAS® instrument is based upon LBT’s intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.


ASX Release 9th June 2020

VIDEO

arrow-down-2 Created with Sketch.


LBT secures first UK sales with Sonic Healthcare subsidiary

LBT secures first U.K. sales with Sonic Healthcare subsidiary

LBT revolutionizes the US$3.9b clinical microbiology industry




Investor Updates with Brent Barnes, LBT Innovations - talks about the year that was and the strategy into 2021 and beyond - December 2020



APAS Independence installation at Halo, HSL, London.




LBT Innovations - Quarterly Investor Video with Brent Barnes - October 2020




Investor Updates with LBT Innovations - July 2020




LBT Innovations on The Market Herald Live - July 2020





LBT Innovations Executive Series - July 2020




LBT Innovations  - Beckman Coulter July



LBT Innovations (ASX:LBT) APAS passes Johns Hopkins test with flying colours





Johns Hopkins Independent Study - LBT Innovations 26 June 2020




Investor Q&A with Dr Glen Hansen - 3rd March 2020


(20min delay)
Last
8.6¢
Change
0.000(0.00%)
Mkt cap ! $24.86M
Open High Low Value Volume
8.5¢ 8.7¢ 8.5¢ $19.78K 229.5K

Buyers (Bids)

No. Vol. Price($)
1 9126 8.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.7¢ 29450 1
View Market Depth
Last trade - 15.53pm 14/06/2021 (20 minute delay) ?
(live)
Last
8.7¢
  Change
0.000 ( 3.57 %)
Open High Low Volume
8.7¢ 8.7¢ 8.7¢ 5550
Last updated 13.50pm 14/06/2021 (live) ?
LBT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.